---
edited: 2024-03-02
tags:
  - dermatology
  - medicine
---
### Clinical spectrum
- [[Mucocutaneous leishmaniasis]] 
- [[Visceral leishmaniasis]] 
### Diagnostics
- Tissue sample should be taken from preferred sites
	- tissue sample (e.g., via biopsy, aspirate, scraping, or brushing) of a cleaned, active lesion for mucocutaneous leishmaniasis
	- Specimen: bone marrow (preferred), liver, lymph node in visceral disease
- Diagnostic tests (perform all 3)
	- Microscopy: Macrophages with amastigotes
	- Culture in Novy-MacNeal-Nicolle medium
	- Molecular testing: PCR

### Management

| Treatment    | Drug                                                              | Dose (CDC)             | Administration Schedule                           | ADRS                                 |
| ------------ | ----------------------------------------------------------------- | ---------------------- | ------------------------------------------------- | ------------------------------------ |
| Preferred    | Liposomal [[Amphotericin B]]                                      | 3 mg/kg IV daily       | Days 1–5, 14, and 21 for immunocompetent patients | [[Thrombophlebitis]]                 |
| Alternatives | Miltefosine (100 mg for weight > 25 kg and half dose for < 25 kg) | 2.5 mg/kg for children | Daily for 28 days                                 | Teratogenicity                       |
|              | Pentavalent antimonial (e.g., sodium stibogluconate)              | 20 mg/kg               | Daily or alternate day injections for 20 days     | [[Pancreatitis]], [[Cardiotoxicity]] |
|              | Pentamidine                                                       |                        | Daily or alternate day injections for 20 days     | [[Type 1 DM]]                        |
|              | Paromomycin                                                       | 11 mg/kg IM            | Daily for 21 days                                 |                                      |

2019 National Guidelines to Eliminate Kala-azar

| Treatment | Dosage                            | Administration Schedule                                                     |
| --------- | --------------------------------- | --------------------------------------------------------------------------- |
| 1st Line  | Liposomal Amphotericin B (L-AMB)  | 10 mg/kg single dose over 2 hrs mixed with dextrose                         |
| 2nd Line  | Half dose L-AMB + Miltefosine     | 7 days                                                                      |
|           |                                   | Paromomycin for 10 days, or                                                 |
|           |                                   | M+P for 10 days                                                             |
| 3rd Line  | Amphotericin B Deoxycholate (AMB) | 1 mg/kg infusion per day over 4 hrs daily or alternate days for 15-20 doses |
| 4th Line  | Paromomycin or Miltefosine        |                                                                             |

---
### Complications
- [[Post-kala azar dermal leishmaniasis]] 
- [[Hemophagocytic lymphohistiocytosis]]
- Opportunistic infections